Metoprolol Succinate Tablet, Film Coated, Extended Release
Product Images NDC 72162-1857

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 72162-1857). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl721621857)

Label (Lbl721621857)
This text describes a medication in the form of film-coated tablets containing 47.5 mg of metoprolol succinate, USP equivalent to 50 mg of metoprolol tartrate, USP. The warning advises keeping the medication out of the reach of children. The storage instructions indicate keeping the tablets at 25°C (77°F) with permitted excursions to 15° to 30°C (59° to 86°F). The prescription information includes details about verifying product dispensed, with 100 tablets being the quantity. The medication is labeled as being relabeled by Bryant Ranch Prepack, Inc. and manufactured by Alkem Laboratories. Pharmacists are instructed to dispense the patient package. Additionally, the text provides a link to further information online.*
FDA Label Image

Metoprolol-structure (Metoprolol Structure)

Metoprolol-structure (Metoprolol Structure)
FDA Label Image

Metoprolol-table1a (Metoprolol Table1a)

Metoprolol-table1a (Metoprolol Table1a)
The text refers to results for subgroups in the MERIT-HF study, focusing on the impact of metoprolol succinate extended-release tablets compared to placebo on total mortality and hospitalization for heart failure. The study includes analysis based on various factors such as NYHA classification, ejection fraction, etiology of heart failure, sex, race, and medical history. Results are presented using relative risk and 95% confidence intervals. The study distinguishes between different patient profiles to provide comprehensive insights into the effects of metoprolol succinate on heart failure outcomes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.